Evidence map›Paper›PMID 32532104›Full record

ArticleCancers2020

TP53-Deficient Angiosarcoma Expression Profiling in Rat Model.

Urszula Smyczyńska, Damian Strzemecki, Anna M Czarnecka, Wojciech Fendler, Michał Fiedorowicz, Marlena Wełniak-Kamińska, Magdalena Guzowska, Kamil Synoradzki, Łukasz Cheda, Zbigniew Rogulski and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Identification ofTranslational cancer research · 2023
    Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

Urszula SmyczyńskaDepartment of Biostatistics and Translational Medicine, Medical University of Lodz, 92-215 Lodz, Poland.
Damian StrzemeckiDepartment of Experimental Pharmacology, Mossakowski Medical Research Centre, Polish Academy of Sciences, 02-106 Warsaw, Poland.
Anna M CzarneckaDepartment of Experimental Pharmacology, Mossakowski Medical Research Centre, Polish Academy of Sciences, 02-106 Warsaw, Poland.ORCID 0000-0002-2107-3810
Wojciech FendlerDepartment of Biostatistics and Translational Medicine, Medical University of Lodz, 92-215 Lodz, Poland.
Michał FiedorowiczDepartment of Experimental Pharmacology, Mossakowski Medical Research Centre, Polish Academy of Sciences, 02-106 Warsaw, Poland.ORCID 0000-0001-5755-3608
Marlena Wełniak-KamińskaDepartment of Experimental Pharmacology, Mossakowski Medical Research Centre, Polish Academy of Sciences, 02-106 Warsaw, Poland.
Magdalena GuzowskaDepartment of Experimental Pharmacology, Mossakowski Medical Research Centre, Polish Academy of Sciences, 02-106 Warsaw, Poland.
Kamil SynoradzkiDepartment of Experimental Pharmacology, Mossakowski Medical Research Centre, Polish Academy of Sciences, 02-106 Warsaw, Poland.
Łukasz ChedaFaculty of Chemistry, Biological and Chemical Research Centre, University of Warsaw, 02-093 Warsaw, Poland.
Zbigniew RogulskiFaculty of Chemistry, Biological and Chemical Research Centre, University of Warsaw, 02-093 Warsaw, Poland.
Paweł GriebDepartment of Experimental Pharmacology, Mossakowski Medical Research Centre, Polish Academy of Sciences, 02-106 Warsaw, Poland.ORCID 0000-0002-6983-7947
Mossakowski Medical Research Institute, Polish Academy of Sciences · PLUniversity of Warsaw · PLDana-Farber Cancer Institute · USMedical University of Lodz · PLThe Maria Sklodowska-Curie National Research Institute of Oncology · PLWarsaw University of Life Sciences · PL

Funding

European Regional Development Fund POIG.02.02.00-14-024/08
6 · The paper itself

Abstract

Sarcomas are a heterogeneous group of malignant tumors, that develop from mesenchymal cells. Sarcomas are tumors associated with poor prognosis and expected short overall survival. Efforts to improve treatment efficacy and treatment outcomes of advanced and metastatic sarcoma patients have not led to significant improvements in the last decades. In the

Indexed as

angiosarcomamicroarray analysisp53 TGEM RatTP53

Identifiers

PMID32532104
PMCPMC7352674
OpenAlexW3034550020

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.